High-Value Disease Biomarkers

High-Value Disease Biomarkers

Biomarkers are defined as a  characteristic that is objectively quantified and evaluated as an indicator of physiological  processes, pathological processes, or pharmacologic responses to a therapy. Biomarkers  can implicate various health and disease characteristics, such as the level or  type of exposure to an environmental factor, genetic susceptibility, markers of  subclinical or clinical disease, or indicators of response to therapy. Biomarkers  can be categorized as antecedent biomarkers, screening biomarkers, diagnostic  biomarkers, staging biomarkers or prognostic biomarkers. Biomarkers exist in various  forms, such as particular hormones (e.g., TSH in Hashimoto's Disease),  metabolites (e.g., phenylalanine in urine of newborns with phenylketonuria),  antibodies (e.g., anti-citrullinated protein antibodies for rheumatoid  arthritis), proteins or peptides (e.g., PSA as an indicator of increased risk  for prostate cancer), cell types (e.g., white blood cell counts in infection or  cancer) and enzyme levels (e.g., various hepatic enzymes for liver cancer).

Biomarkers can also be used to evaluate  the effectiveness of particular therapies in treating a disease. By measuring  drug response rate or toxic effects associated with the drug, specific biomarkers  can be used to monitor a patient's reaction to a particular drug, checking  whether the treatment is effective and facilitating earlier detection of  adverse drug response. Biomarkers also play an important role in the  development of new drugs with the discovery of "druggable targets."  Alterations in the progression markers can be used to understand whether and  how a disease is slowed or reversed by a new therapy, which allows researchers  to focus efforts and resources on the most effective ones. Finally, biomarkers  can be used to evaluate the progression of a disease or the susceptibility of a  disease to a given treatment and hold great promise for personalized medicine. The  treatment will be tailored and the most efficient intervention for each  individual will be used.

Quantification of biomarkers can be  used in various fields, such as basic research, drug development, and clinical  practice. The quantification can provide a framework for development and  regulatory acceptance of biomarkers used in drug development. A big challenge  in biomarker quantification is the need to reduce sample complexity while  minimizing errors during sample handling at the same time. A HPLC  chromatographic separation is often used before mass spectrometric  analysis. The improved derivatization techniques, improved sensitivity as  well as enhanced speed of MS allowed for the higher sensitivity for the  analysis of complex samples with accuracy. The recent advance of MS analyses  have greatly contributed to the quantification of biomarkers, minimizing the  time and costs for quantification of multiple samples.



Sample Requirement


High-Value Disease Biomarkers Quantified in This Service

With integrated set of separation,  characterization, identification and quantification systems featured with  excellent robustness & reproducibility, high and ultra-sensitivity, Creative Proteomics provides  reliable, rapid and cost-effective High-Value Disease Biomarkers targeted metabolomics services.

* For Research Use Only. Not for use in diagnostic procedures.
Our customer service representatives are available 24 hours a day, 7 days a week. Inquiry
Online Inquiry

Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to for inquiries.

  • Verification Code

Stay in Contact

  • 45-1 Ramsey Road, Shirley, NY 11967, USA
  • Tel: 1-631-275-3058 (USA)
  • Tel: 44-208-144-6005 (Europe)
  • Fax: 1-631-614-7828
  • Email:
© 2008-2021 Creative Proteomics. All rights reserved.